Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Safety remains in focus for Cogent’s bezuclastinib
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
Mesothelin lives on
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
Lack of overall survival doesn't stop Flaura2
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
Black Diamond picks its lung cancer battle
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
Venture cash funds first human trials
Private company trial initiations stand out in the latest week’s disclosures.
